rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    MBX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Mbx Biosciences ceo Steven Hoerter sells $268,234 in shares
      Nov 15Investing.comMBX
      This Kimball Electronics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
      Nov 12BenzingaKEMBX
      Citizens reiterates MBX Biosciences stock rating on GLP agonist data
      Nov 12Investing.comMBX
      MBX Biosciences at Guggenheim: rare disease gains, obesity bets
      Nov 10Investing.comMBX
      MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights
      Nov 9Yahoo FinanceMBX
      MBX Biosciences stock maintained at Buy by Truist on obesity drug
      Oct 29Investing.comMBXTFC
      Citizens reiterates Market Outperform on MBX Biosciences stock
      Oct 27Investing.comMBX
      MBX Biosciences appoints Peter Radovich to board as independent director
      Oct 22Investing.comMBX
      MBX Biosciences to Participate in Upcoming November Investor Conferences
      Oct 13Yahoo FinanceMBX
      Analysts Offer Insights on NA Companies: X-Energy, Inc. Class A (XE) and MBX Biosciences, Inc. (MBX)

      Detailed price information for Mbx Biosciences Inc (MBX-Q) from The Globe and Mail including charting and trades.

      Oct 13The Globe and MailMBX
      Stifel raises MBX Biosciences price target to $84 on obesity drug data
      Oct 12Investing.comMBX
      Is MBX Biosciences (MBX) Still Undervalued After Its Pullback From A Strong 1 Year Run?
      Oct 10Yahoo FinanceMBX
      MBX Biosciences (MBX) Stock Could Be Above Fair Value As Shares Jumped 257%
      Oct 10Yahoo FinanceMBX
      Guggenheim raises MBX Biosciences price target to $150 on obesity drug potential
      Oct 2Investing.comMBX
      MBX Biosciences at stifel cardiometabolic forum: pipeline bets on dosing edge
      Sep 30Investing.comMBX
      UBS reiterates Buy on MBX Biosciences stock ahead of Q4 obesity data
      Sep 28Investing.comMBXUBS
      Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday
      Sep 28BenzingaAGENKODMBXAMC
      MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade) (NASDAQ:MBX)
      Sep 23Seeking AlphaMBX
      MBX Biosciences at Morgan Stanley conference: pipeline nears key tests
      Sep 16Investing.comMBXMS
      MBX Biosciences to Participate in Upcoming Investor Conferences

      CARMEL, Ind., and BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Steve Hoerter, Chairman and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at, and participate in, the following upcoming investor confer

      Sep 9Yahoo FinanceMBX
      MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer

      CARMEL, Ind. and BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Jeff Held, J.D., as Chief Legal Officer. Mr. Held brings more than three decades of legal, compliance and executive leadership experience across biotechnology, l

      Sep 8Yahoo FinanceMBX
      MBX Biosciences doses first patient in phase 3 HP trial
      Aug 27Investing.comMBXHPQ
      MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism

      Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support once-weekly canvuparatide’s potential as a best-in-class PTH replacement therapy CARMEL, Ind., and BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide

      Aug 27Yahoo FinanceMBX

      This is the newest page. Registered accounts read further back.